Trial Profile
An open label, randomized study for the comparison of effectiveness between glucagon-like peptide-1 (GLP-1) analogue in people with type 2 diabetes treated bolus first or basal first insulin therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Dec 2018
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Liraglutide (Primary) ; Insulin glargine; Insulin glulisine
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Therapeutic Use
- 29 Nov 2018 Status changed from recruiting to completed.
- 08 Apr 2013 New trial record